Coronary Stent Thrombosis in 2015: A Comprehensive and Uptodated&nbsp;Review

Bernardo Cortese; Davide Piraino; Eluisa La Franca; Dario Buccheri; Pedro Silva Orrego; Giuseppe Andolina; Romano Seregni; Bernardo Cortese; Davide Piraino; Eluisa La Franca; Dario Buccheri; Pedro Silva Orrego; Giuseppe Andolina; Romano Seregni

doi:10.3934/medsci.2015.3.131

AIMS Medical Science

2015, Volume 2, Issue 3: 131-149. doi: 10.3934/medsci.2015.3.131

Previous Article Next Article

Review Special Issues

Coronary Stent Thrombosis in 2015: A Comprehensive and Uptodated Review

1.
Cardiologia Interventistica, A.O. Fatebenefratelli Milano, Italy;
2.
Cardiologia Interventistica ed Emodinamica, Policlinico “P. Giaccone”, Palermo, Italy

Received: 09 April 2015 Accepted: 28 July 2015 Published: 30 July 2015

Stent thrombosis (ST) is a life-threatening, although quite rare, complication of percutaneous coronary intervention with stenting. According to the Academic Research Consortium, it may be defined as definite, probable, or possible. Moreover, its occurrence after index procedure differentiates between early, late and very late. This complication is associated with high morbidity and mortality and has a very high impact on global health of patients with cardiovascular disorders, therefore a multifactorial approach seems a useful tool for understanding its causes and improving its outcome. In this review we analyze all the most important issues of this disorder beginning from its classification, then we overview the pathophysiological mechanisms and factors implicated and, lastly, we give a glimpse to the future perspective on prevention strategies.
- stent thrombosis,
- PCI,
- long term follow up,
- DES,
- BMS
Citation: Bernardo Cortese, Davide Piraino, Eluisa La Franca, Dario Buccheri, Pedro Silva Orrego, Giuseppe Andolina, Romano Seregni. Coronary Stent Thrombosis in 2015: A Comprehensive and Uptodated Review[J]. AIMS Medical Science, 2015, 2(3): 131-149. doi: 10.3934/medsci.2015.3.131

Related Papers:

Abstract

Stent thrombosis (ST) is a life-threatening, although quite rare, complication of percutaneous coronary intervention with stenting. According to the Academic Research Consortium, it may be defined as definite, probable, or possible. Moreover, its occurrence after index procedure differentiates between early, late and very late. This complication is associated with high morbidity and mortality and has a very high impact on global health of patients with cardiovascular disorders, therefore a multifactorial approach seems a useful tool for understanding its causes and improving its outcome. In this review we analyze all the most important issues of this disorder beginning from its classification, then we overview the pathophysiological mechanisms and factors implicated and, lastly, we give a glimpse to the future perspective on prevention strategies.

References

[1]	Cutlip DE, Baim DS, Ho KK, et al. (2001) Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103: 1967-1971. doi: 10.1161/01.CIR.103.15.1967
[2]	Ong AT, Hoye A, Aoki J, et al. (2005) Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45: 947-953. doi: 10.1016/j.jacc.2004.09.079
[3]	Cutlip DE, Windecker S, Mehran R, et al. (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115: 2344-2351. doi: 10.1161/CIRCULATIONAHA.106.685313
[4]	Cutlip DE, Nakazawa G, Krucoff MW, et al. (2011) Autopsy validation study of the academic research consortium stent thrombosis definition. JACC Cardiovasc Interv 4: 554-559. doi: 10.1016/j.jcin.2011.01.011
[5]	Dangas GD, Serruys PW, Kereiakes DJ, et al. (2013) Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 6: 914-922. doi: 10.1016/j.jcin.2013.05.005
[6]	Wenaweser P, Daemen J, Zwahlen M, et al. (2008) Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 52: 1134-1140.
[7]	Stone GW, Ellis SG, Cox DA, et al. (2004) One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109: 1942-1947. doi: 10.1161/01.CIR.0000127110.49192.72
[8]	Moreno R, Fernandez C, Hernandez R, et al. (2005) Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45: 954-959. doi: 10.1016/j.jacc.2004.11.065
[9]	Ellis SG, Colombo A, Grube E, et al. (2007) Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 49: 1043-1051. doi: 10.1016/j.jacc.2007.01.015
[10]	Kolandaivelu K, Swaminathan R, Gibson WJ, et al. (2011) Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123: 1400-1409. doi: 10.1161/CIRCULATIONAHA.110.003210
[11]	Stone GW, Moses JW, Ellis SG, et al. (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356: 998-1008. doi: 10.1056/NEJMoa067193
[12]	Tada T, Byrne RA, Simunovic I, et al. (2013) Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv 6: 1267-1274. doi: 10.1016/j.jcin.2013.06.015
[13]	Kirtane AJ, Stone GW (2011) How to minimize stent thrombosis. Circulation 124: 1283-1287. doi: 10.1161/CIRCULATIONAHA.110.976829
[14]	Cook S, Ladich E, Nakazawa G, et al. (2009) Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 120: 391-399. doi: 10.1161/CIRCULATIONAHA.109.854398
[15]	Alfonso F, Suarez A, Angiolillo DJ, et al. (2004) Findings of intravascular ultrasound during acute stent thrombosis. Heart 90: 1455-1459. doi: 10.1136/hrt.2003.026047
[16]	van Werkum JW, Heestermans AA, Zomer AC, et al. (2009) Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 53: 1399-1409. doi: 10.1016/j.jacc.2008.12.055
[17]	Gonzalo N, Barlis P, Serruys PW, et al. (2009) Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography. JACC Cardiovasc Interv 2: 445-452. doi: 10.1016/j.jcin.2009.01.012
[18]	ide la Torre-Hernandez JM, Alfonso F, Hernandez F, et al. (2008) Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 51: 986-990. doi: 10.1016/j.jacc.2007.10.057
[19]	Motovska Z, Knot J, Widimsky P (2010) Stent thrombosis--risk assessment and prevention. Cardiovasc Ther 28: e92-100. doi: 10.1111/j.1755-5922.2010.00186.x
[20]	Kukreja N, Onuma Y, Garcia-Garcia HM, et al. (2009) The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2: 534-541. doi: 10.1016/j.jcin.2009.04.003
[21]	Cheneau E, Leborgne L, Mintz GS, et al. (2003) Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 108: 43-47. doi: 10.1161/01.CIR.0000078636.71728.40
[22]	Nakazawa G (2011) Stent thrombosis of drug eluting stent: pathological perspective. J Cardiol 58: 84-91. doi: 10.1016/j.jjcc.2011.07.004
[23]	Robbins SL KV, Cotran RS (2010) Robbins and Cotran Pathologic Basis of desease
[24]	Virmani R, Guagliumi G, Farb A, et al. (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109: 701-705. doi: 10.1161/01.CIR.0000116202.41966.D4
[25]	Siqueira DA, Abizaid AA, Costa Jde R, et al. (2007) Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur Heart J 28: 1304-1309. doi: 10.1093/eurheartj/ehm114
[26]	Iakovou I, Schmidt T, Bonizzoni E, et al. (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293: 2126-2130. doi: 10.1001/jama.293.17.2126
[27]	Hoye A, Iakovou I, Ge L, et al. (2006) Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. J Am Coll Cardiol 47: 1949-1958. doi: 10.1016/j.jacc.2005.11.083
[28]	Ge L, Airoldi F, Iakovou I, et al. (2005) Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol 46: 613-620. doi: 10.1016/j.jacc.2005.05.032
[29]	Otsuka F, Byrne RA, Yahagi K, et al. (2015) Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J.
[30]	Finn AV, Otsuka F (2012) Neoatherosclerosis: a culprit in very late stent thrombosis. Circ Cardiovasc Interv 5: 6-9. doi: 10.1161/CIRCINTERVENTIONS.111.967927
[31]	Nakazawa G, Otsuka F, Nakano M, et al. (2011) The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 57: 1314-1322. doi: 10.1016/j.jacc.2011.01.011
[32]	Yamaji K, Inoue K, Nakahashi T, et al. (2012) Bare metal stent thrombosis and in-stent neoatherosclerosis. Circ Cardiovasc Interv 5: 47-54. doi: 10.1161/CIRCINTERVENTIONS.111.964965
[33]	Finn AV, Nakazawa G, Joner M, et al. (2007) Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27: 1500-1510. doi: 10.1161/ATVBAHA.107.144220
[34]	Marchini JF, Gomes WF, Moulin B, et al. (2014) Very late outcomes of drug-eluting stents coated with biodegradable polymers: insights from the 5-year follow-up of the randomized PAINT trial. Cardiovasc Diagn Ther 4: 480-486.
[35]	Bangalore S, Toklu B, Amoroso N, et al. (2013) Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ 347: f6625. doi: 10.1136/bmj.f6625
[36]	Dudek D, Onuma Y, Ormiston JA, et al. (2012) Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 7: 1060-1061. doi: 10.4244/EIJV7I9A168
[37]	Kuchulakanti PK, Chu WW, Torguson R, et al. (2006) Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113: 1108-1113. doi: 10.1161/CIRCULATIONAHA.105.600155
[38]	Jeremias A, Sylvia B, Bridges J, et al. (2004) Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109: 1930-1932. doi: 10.1161/01.CIR.0000127105.99982.21
[39]	Eisenstein EL, Anstrom KJ, Kong DF, et al. (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297: 159-168. doi: 10.1001/jama.297.2.joc60179
[40]	Spertus JA, Kettelkamp R, Vance C, et al. (2006) Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113: 2803-2809. doi: 10.1161/CIRCULATIONAHA.106.618066
[41]	Wiviott SD, Braunwald E, McCabe CH, et al. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015. doi: 10.1056/NEJMoa0706482
[42]	Wallentin L, Becker RC, Budaj A, et al. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057. doi: 10.1056/NEJMoa0904327
[43]	Windecker S, Kolh P, Alfonso F, et al. (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35: 2541-2619. doi: 10.1093/eurheartj/ehu278
[44]	Levine GN, Bates ER, Blankenship JC, et al. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58: e44-122.
[45]	Cortese B, Sebik R, Valgimigli M (2014) The conundrum of antithrombotic drugs before, during and after primary PCI. EuroIntervention 10 Suppl T: T64-73.
[46]	Mauri L, Kereiakes DJ, Yeh RW, et al. (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371: 2155-2166. doi: 10.1056/NEJMoa1409312
[47]	Ferreira-Gonzalez I, Marsal JR, Ribera A, et al. (2010) Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation 122: 1017-1025. doi: 10.1161/CIRCULATIONAHA.110.938290
[48]	Lordkipanidze M, Pharand C, Schampaert E, et al. (2007) A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28: 1702-1708. doi: 10.1093/eurheartj/ehm226
[49]	Lev EI, Patel RT, Maresh KJ, et al. (2006) Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47: 27-33. doi: 10.1016/j.jacc.2005.08.058
[50]	Cooke GE, Liu-Stratton Y, Ferketich AK, et al. (2006) Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 47: 541-546. doi: 10.1016/j.jacc.2005.09.034
[51]	Siller-Matula J, Schror K, Wojta J, et al. (2007) Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 97: 385-393.
[52]	Mason PJ, Freedman JE, Jacobs AK (2004) Aspirin resistance: current concepts. Rev Cardiovasc Med 5: 156-163. doi: 10.1016/j.carrev.2005.01.001
[53]	Mason PJ, Jacobs AK, Freedman JE (2005) Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 46: 986-993. doi: 10.1016/j.jacc.2004.08.070
[54]	Buonamici P, Marcucci R, Migliorini A, et al. (2007) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49: 2312-2317. doi: 10.1016/j.jacc.2007.01.094
[55]	Cuisset T, Frere C, Quilici J, et al. (2006) High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4: 542-549. doi: 10.1111/j.1538-7836.2005.01751.x
[56]	Wenaweser P, Dorffler-Melly J, Imboden K, et al. (2005) Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45: 1748-1752. doi: 10.1016/j.jacc.2005.01.058
[57]	Walter DH, Schachinger V, Elsner M, et al. (1997) Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 350: 1217-1219. doi: 10.1016/S0140-6736(97)05399-3
[58]	Fiore M, Horovitz A, Pons AC, et al. (2014) First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor. Platelets 25: 636-638. doi: 10.3109/09537104.2013.852659
[59]	Daemen J, Wenaweser P, Tsuchida K, et al. (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369: 667-678. doi: 10.1016/S0140-6736(07)60314-6
[60]	Herzog CA, Ma JZ, Collins AJ (2002) Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 106: 2207-2211. doi: 10.1161/01.CIR.0000035248.71165.EB
[61]	Gruberg L, Mintz GS, Mehran R, et al. (2000) The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 36: 1542-1548. doi: 10.1016/S0735-1097(00)00917-7
[62]	Rubenstein MH, Harrell LC, Sheynberg BV, et al. (2000) Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 102: 2966-2972. doi: 10.1161/01.CIR.102.24.2966
[63]	Wiviott SD, Braunwald E, Angiolillo DJ, et al. (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118: 1626-1636. doi: 10.1161/CIRCULATIONAHA.108.791061
[64]	Dangas GD, Caixeta A, Mehran R, et al. (2011) Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 123: 1745-1756. doi: 10.1161/CIRCULATIONAHA.110.981688
[65]	Armstrong EJ, Feldman DN, Wang TY, et al. (2012) Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv 5: 131-140.
[66]	Kimura T, Morimoto T, Kozuma K, et al. (2010) Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 122: 52-61. doi: 10.1161/CIRCULATIONAHA.109.903955
[67]	Yeo KK, Armstrong EJ, Soni K, et al. (2015) Long-term outcomes of angiographically confirmed coronary stent thrombosis: results from a multicentre California registry. EuroIntervention 11: 188-195. doi: 10.4244/EIJV11I2A33
[68]	Roe MT, Messenger JC, Weintraub WS, et al. (2010) Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol 56: 254-263. doi: 10.1016/j.jacc.2010.05.008
[69]	Secemsky EA, Matteau A, Yeh RW, et al. (2015) Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials). Am J Cardiol 115: 1678-1684. doi: 10.1016/j.amjcard.2015.03.010
[70]	Chechi T, Vecchio S, Vittori G, et al. (2008) ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol 51: 2396-2402. doi: 10.1016/j.jacc.2008.01.070
[71]	Sianos G, Papafaklis MI, Daemen J, et al. (2007) Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol 50: 573-583. doi: 10.1016/j.jacc.2007.04.059
[72]	Kianoush S, Bikdeli B, Desai MM, et al. (2015) Risk of Stent Thrombosis and Major Bleeding with Bivalirudin Compared with Active Control: A Systematic Review and Meta-analysis of Randomized Trials. Thromb Res.
[73]	Verdoia M, Schaffer A, Barbieri L, et al. (2015) Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: A meta-analysis of 22 randomized trials. Thromb Res 135: 902-915. doi: 10.1016/j.thromres.2015.03.004
[74]	Stone GW, Witzenbichler B, Guagliumi G, et al. (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358: 2218-2230. doi: 10.1056/NEJMoa0708191
[75]	Gurbel PA, Navarese EP, Tantry US (2015) What is the best anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction? Pol Arch Med Wewn.
[76]	Nairooz R, Sardar P, Amin H, et al. (2014) Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction. Am J Cardiol 114: 250-259. doi: 10.1016/j.amjcard.2014.04.033
[77]	Cortese B, Limbruno U, Severi S, et al. (2011) Effect of Prolonged Bivalirudin Infusion on ST-Segment Resolution Following Primary Percutaneous Coronary Intervention (from the PROBI VIRI 2 Study). Am J Cardiol 108:1220-1224. doi: 10.1016/j.amjcard.2011.06.033
[78]	Lupi a, Rognoni A, Cavallino C, et al. (2015) Eur Heart J Acute Card Care Epub ahead of print.
[79]	Palmerini T, Biondi-Zoccai G, Stone GW (2014) Stent selection to minimize the risk of stent thrombosis. Curr Opin Cardiol 29: 578-585. doi: 10.1097/HCO.0000000000000102
[80]	Cortese B, Bertoletti A (2012) Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol 161: 4-12. doi: 10.1016/j.ijcard.2011.08.855
[81]	Prati F, Kodama T, Romagnoli E, et al. (2015) Suboptimal stent deployment is associated with subacute stent thrombosis: optical coherence tomography insights from a multicenter matched study. From the CLI Foundation investigators: the CLI-THRO study. Am Heart J 169: 249-256.
[82]	Verdoia M, Schaffer A, Barbieri L, et al. (2015) Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials. Angiology.

Reader Comments

Your name:*

Email:*
© 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)